EQRx, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About EQRx, Inc.

EQRx, Inc. is a U.S. biopharmaceutical company founded in 2019 and based in Cambridge, Massachusetts, United States. It was formerly listed on the U.S. Nasdaq market before being acquired by Revolution Medicines in November 2023. The company became known for a highly differentiated investment thesis: developing innovative medicines with a strong emphasis on making them available at substantially lower prices than those typically seen in the pharmaceutical industry. For investors, this made EQRx an attention-grabbing healthcare story, although it now has to be viewed primarily through the lens of its post-acquisition status. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1843762/000155837023001902/eqrx-20221231x10k.htm?utm_source=openai)) Operationally, EQRx focused on oncology and immune-inflammatory diseases. According to its SEC filings, the company had more than ten programs across clinical, preclinical, and drug-engineering stages, which underscores that EQRx was built as a pipeline-driven biotech rather than a single-asset developer. Its strategy centered on identifying, advancing, and eventually commercializing innovative medicines for large patient populations and areas with meaningful unmet medical need. The company’s scientific model combined clinical development capabilities with a strong emphasis on access, pricing discipline, and portfolio selection. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1843762/000155837023001902/eqrx-20221231x10k.htm?utm_source=openai)) EQRx was founded by well-known industry figures, including Alexis Borisy and Sandra Horning, which helped establish credibility in the Cambridge life-sciences ecosystem. Its principal executive office was located at 50 Hampshire Street in Cambridge, Massachusetts 02139, placing it in one of the world’s leading biotechnology clusters. That location supported talent acquisition, investor visibility, and proximity to academic and industry partners, all of which matter significantly in biotech execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1843762/000155837022004161/eqrx-20211231x10k.htm?utm_source=openai)) From a competitive standpoint, EQRx tried to stand apart through its access-and-affordability positioning, a relatively uncommon angle among listed biotech companies. At the same time, it operated in a highly competitive sector dominated by better-capitalized peers with broader pipelines, deeper clinical infrastructure, and greater regulatory experience. This made execution risk, differentiation, and capital efficiency central to the equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1843762/000155837023001902/eqrx-20221231x10k.htm?utm_source=openai)) The most important recent event was Revolution Medicines’ acquisition of EQRx, announced and completed in November 2023. Following closing, EQRx programs were wound down or absorbed into the acquirer’s strategy, and EQRx common stock ceased trading on Nasdaq. For international investors, the key takeaway is that EQRx is no longer an active standalone Nasdaq-listed company; instead, it is best understood as a former U.S. biotech issuer whose recent history is defined by M&A rather than ongoing public-market operations. ([ir.revmed.com](https://ir.revmed.com/node/9866/pdf?utm_source=openai))